Get the Stockscreener App
0.3501
1.46%
-0.0052
Coeptis Therapeutics Holdings Inc stock is currently priced at $0.3501, with a 24-hour trading volume of 34,552.
It has seen a -1.46% decreased in the last 24 hours and a -5.35% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3605 pivot point. If it approaches the $0.3499 support level, significant changes may occur.
Previous Close:
$0.3553
Open:
$0.3502
24h Volume:
34,552
Market Cap:
$13.00M
Revenue:
-
Net Income/Loss:
$-20.19M
P/E Ratio:
-0.3661
EPS:
-0.9564
Net Cash Flow:
$-6.39M
1W Performance:
-8.64%
1M Performance:
-5.35%
6M Performance:
-71.30%
1Y Performance:
-79.76%
1D Range:
$0.3501
$0.38
52W Range:
$0.2851
$2.1899
Coeptis Therapeutics Holdings Inc Stock (COEP) Company Profile
Name
Coeptis Therapeutics Holdings Inc
Sector
Industry
Phone
724 934 6467
Address
105 Bradford Road, Suite 420, Wexford
Coeptis Therapeutics Holdings Inc Stock (COEP) Latest News
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - Nasdaq
Nasdaq
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th ... - PR Newswire
PR Newswire
Coeptis Therapeutics' Dave Mehalick on Making Cell Therapy Universally Accessible - InvestorNews - InvestorNews Inc.
InvestorNews Inc.
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 ... - PR Newswire
PR Newswire
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the ... - PR Newswire
PR Newswire
Coeptis Therapeutics Risks Nasdaq Delisting Over Price - TipRanks.com - TipRanks
TipRanks
Coeptis Therapeutics Holdings Inc Stock (COEP) Financials Data
Coeptis Therapeutics Holdings Inc (COEP) Net Income 2024
COEP net income (TTM) was -$20.19 million for the quarter ending September 30, 2023, a +46.13% increase year-over-year.
Coeptis Therapeutics Holdings Inc (COEP) Cash Flow 2024
COEP recorded a free cash flow (TTM) of -$6.39 million for the quarter ending September 30, 2023, a -97.48% decrease year-over-year.
Coeptis Therapeutics Holdings Inc (COEP) Earnings per Share 2024
COEP earnings per share (TTM) was -$0.9104 for the quarter ending September 30, 2023, a +50.69% growth year-over-year.
About Coeptis Therapeutics Holdings Inc
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors. and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
0.77%
1.20%
Cap:
|
Volume (24h):